The company's platform relies on a method called RABID-seq that combines barcoded viral tracing with single-cell RNA-seq to study interactions between brain cells.
The application was based on results from a Phase I/II trial in which Hyrnuo demonstrated a 71 percent response rate.
The approval is for DEB patients from birth and allows for flexible administration at home by patients or caregivers.
Investigators will analyze CTCs from colon, gastrointestinal, and lung cancer patients to help understand how they respond to exercise regimens.
Investigators will analyze CTCs from colon, gastrointestinal, and lung cancer patients to help understand how they respond to exercise regimens.
The principal investigator reported at the ASGCT meeting that the study met its primary endpoint, though there were two treatment-related serious adverse events.
Even though Arvinas and Pfizer appear to have "written off" the drug, in one analyst's view, Rigel believes it can drive adoption among community-treated patients lacking SERD access.
NEW YORK – The US Food and Drug Administration on Friday approved AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) for two early-stage HER2-positive breast cancer indications, ...
Attendees at a fireside chat at the ASGCT annual meeting noted disconnects between the agency's stated goal of speeding gene therapies to market and its actions.
The latest decision makes these treatments routinely available after having been accessible only through a managed access scheme.
On CGTxchange, sponsors can list their shelved cell and gene therapies in the hopes that other investors, partners, and ...
NEW YORK – Telix is collaborating with two med tech companies to develop ultrasound technologies for treating localized prostate cancer using the firm's radiopharmaceutical imaging agents. For the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results